Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 4/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7217047 | 1.00 | CA1 (0.55) | CA1ACE2ZDHHC7MAPTFAAH | |
| SCHEMBL27901941 | 0.98 | CA1 (0.53) | CA1ACE2ZDHHC7MAPTFAAH | |
| SCHEMBL9728487 | 0.98 | CA1 (0.53) | CA1ACE2ZDHHC7MAPTFAAH | |
| SCHEMBL17435172 | 0.98 | CA1 (0.53) | CA1ACE2ZDHHC7MAPTFAAH | |
| SCHEMBL7223212 | 0.98 | CA1 (0.53) | CA1ACE2ZDHHC7MAPTFAAH | |
| SCHEMBL27906637 | 0.98 | CA1 (0.53) | CA1ACE2ZDHHC7MAPTFAAH | |
| SCHEMBL7218218 | 0.94 | CA1 (0.47) | CA1ACE2FDPSNAAADGKA | |
| SCHEMBL7223259 | 0.92 | CA1 (0.55) | CA1ACE2ZDHHC7MAPTFAAH | |
| SCHEMBL7219469 | 0.92 | CA1 (0.55) | CA1ACE2ZDHHC7MAPTFAAH | |
| SCHEMBL7218790 | 0.90 | CA1 (0.53) | CA1ACE2ZDHHC7MAPTFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170121278-A1 | METHODS AND COMPOSITIONS FOR MAKING AN AMINO ACID TRIISOCYANATE | WARSAW ORTHOPEDIC INC (US) | 2017-05-04 | — | — | US | disclosed |
| US-9573889-B2 | Methods and compositions for making an amino acid triisocyanate | WARSAW ORTHOPEDIC, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160168085-A1 | METHODS AND COMPOSITIONS FOR MAKING AN AMINO ACID TRIISOCYANATE | WARSAW ORTHOPEDIC INC (US) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121278-A1 | METHODS AND COMPOSITIONS FOR MAKING AN AMINO ACID TRIISOCYANATE | AADAT, AGT, PHYKPL | CA1 441/4885ACE2 311/4885ZDHHC7 2824/4885 |
| US-20160168085-A1 | METHODS AND COMPOSITIONS FOR MAKING AN AMINO ACID TRIISOCYANATE | AADAT, AGT, PHYKPL | CA1 441/4885ACE2 311/4885ZDHHC7 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.